HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Fawwaz, R. A. Articles by Alderson, P. O. Search for Related Content PubMed PubMed Citation Articles by Fawwaz, R. A. Articles by Alderson, P. O.

Potential of Palladium-109-Labeled Antimelanoma Monoclonal Antibody for Tumor Therapy

College of Physicians and Surgeons, Columbia University, New York
New York Medical College, Valhalla, and Brookhaven National Laboratory, Upton, New York

Correspondence: For reprints contact: Rashid Fawwaz, MD, PhD, Division of Nuclear Medicine, Columbia-Presbyterian Medical Center, 622 West 168th St., New York, NY 10032.

ABSTRACT

Palladium-109, a beta-emitting radionuclide, was chelated to the monoclonal antibody 225.28S to the high molecular weight antigen associated with human melanoma. The radiolabeled antibody maintained its specific in vitro reactivity with cultured human melanoma cells. Injection of the radiolabeled monoclonal antibody into nude mice bearing human melanoma resulted in significant accumulation of the radiolabel in the tumors: 19% injected dose/g; 38:1 and 61:1 tumor-to-blood ratios at 24 and 48 hr, respectively. The localization of the radiolabeled antibody in liver and kidney also was high, but appreciably lower than that achieved in tumor. These results suggest that Pd-109-labeled monoclonal antibody to tumor-associated antigens may have potential applications in tumor immunotherapy.